As of 2024-07-27, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -2.65. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 497.91 mil USD. FATE's TTM EBITDA according to its financial statements is -188.20 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 16.6x - 25.7x | 20.1x |
| Forward P/E multiples | 24.1x - 30.6x | 25.6x |
| Fair Price | (26.35) - 4.77 | (14.00) |
| Upside | -584.3% - -12.3% | -357.4% |
| Date | EV/EBITDA |
| 2024-07-26 | -2.65 |
| 2024-07-25 | -2.62 |
| 2024-07-24 | -2.49 |
| 2024-07-23 | -2.72 |
| 2024-07-22 | -2.11 |
| 2024-07-19 | -1.94 |
| 2024-07-18 | -1.96 |
| 2024-07-17 | -2.05 |
| 2024-07-16 | -2.11 |
| 2024-07-15 | -1.71 |
| 2024-07-12 | -1.54 |
| 2024-07-11 | -1.41 |
| 2024-07-10 | -1.24 |
| 2024-07-09 | -1.25 |
| 2024-07-08 | -1.24 |
| 2024-07-05 | -1.27 |
| 2024-07-03 | -1.27 |
| 2024-07-02 | -1.30 |
| 2024-07-01 | -1.33 |
| 2024-06-28 | -1.34 |
| 2024-06-27 | -1.33 |
| 2024-06-26 | -1.33 |
| 2024-06-25 | -1.61 |
| 2024-06-24 | -1.68 |
| 2024-06-21 | -1.63 |
| 2024-06-20 | -1.53 |
| 2024-06-18 | -1.42 |
| 2024-06-17 | -1.51 |
| 2024-06-14 | -1.54 |
| 2024-06-13 | -1.63 |
| 2024-06-12 | -1.64 |
| 2024-06-11 | -1.71 |
| 2024-06-10 | -1.69 |
| 2024-06-07 | -1.58 |
| 2024-06-06 | -1.65 |
| 2024-06-05 | -1.63 |
| 2024-06-04 | -1.57 |
| 2024-06-03 | -1.58 |
| 2024-05-31 | -1.58 |
| 2024-05-30 | -1.44 |
| 2024-05-29 | -1.43 |
| 2024-05-28 | -1.50 |
| 2024-05-24 | -1.48 |
| 2024-05-23 | -1.43 |
| 2024-05-22 | -1.56 |
| 2024-05-21 | -1.59 |
| 2024-05-20 | -1.72 |
| 2024-05-17 | -1.71 |
| 2024-05-16 | -1.86 |
| 2024-05-15 | -1.92 |